Estramustine phosphate-hormone, chemotherapeutic agent, or both?

Yair Walzer, Joye Oswalt, Mark S. Soloway

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Estramustine phosphate, a combination steroid and alkylating agent, has been used for treatment of cancer of the prostate since 1969. We treated 32 patients with Stages C and D prostate cancer with this compound. Using the National Prostatic Cancer Project criteria of response, no patient achieved complete or partial objective response. Sixty-two per cent of the patients without prior hormonal manipulation and 12 per cent of those who were progressing following hormonal therapy met the criteria for a stable response. Both Stage C patients, 50 per cent of D1 and 28 per cent of D2 patients achieved disease stabilization for a mean duration of 14.8 months. There was no correlation between tumor grade and response to treatment. Fifty per cent of the patients whose elevated acid phosphatase declined remain stable, whereas 80 per cent in whom the acid phosphatase did not decline have progressed. Estramustine is effective in patients without prior hormonal manipulation. In those refractory to hormones, the prognosis is poor yet data exist to support the superiority of estramustine phosphate over conventional therapy.

Original languageEnglish
Pages (from-to)53-58
Number of pages6
JournalUrology
Volume24
Issue number1
DOIs
StatePublished - Jan 1 1984
Externally publishedYes

Fingerprint

Estramustine
Phosphates
Hormones
Prostatic Neoplasms
Acid Phosphatase
Alkylating Agents
Therapeutics
Steroids

ASJC Scopus subject areas

  • Urology

Cite this

Estramustine phosphate-hormone, chemotherapeutic agent, or both? / Walzer, Yair; Oswalt, Joye; Soloway, Mark S.

In: Urology, Vol. 24, No. 1, 01.01.1984, p. 53-58.

Research output: Contribution to journalArticle

Walzer, Yair ; Oswalt, Joye ; Soloway, Mark S. / Estramustine phosphate-hormone, chemotherapeutic agent, or both?. In: Urology. 1984 ; Vol. 24, No. 1. pp. 53-58.
@article{10407b01bb394f37a402183b4c84dd07,
title = "Estramustine phosphate-hormone, chemotherapeutic agent, or both?",
abstract = "Estramustine phosphate, a combination steroid and alkylating agent, has been used for treatment of cancer of the prostate since 1969. We treated 32 patients with Stages C and D prostate cancer with this compound. Using the National Prostatic Cancer Project criteria of response, no patient achieved complete or partial objective response. Sixty-two per cent of the patients without prior hormonal manipulation and 12 per cent of those who were progressing following hormonal therapy met the criteria for a stable response. Both Stage C patients, 50 per cent of D1 and 28 per cent of D2 patients achieved disease stabilization for a mean duration of 14.8 months. There was no correlation between tumor grade and response to treatment. Fifty per cent of the patients whose elevated acid phosphatase declined remain stable, whereas 80 per cent in whom the acid phosphatase did not decline have progressed. Estramustine is effective in patients without prior hormonal manipulation. In those refractory to hormones, the prognosis is poor yet data exist to support the superiority of estramustine phosphate over conventional therapy.",
author = "Yair Walzer and Joye Oswalt and Soloway, {Mark S.}",
year = "1984",
month = "1",
day = "1",
doi = "10.1016/0090-4295(84)90388-1",
language = "English",
volume = "24",
pages = "53--58",
journal = "Urology",
issn = "0090-4295",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Estramustine phosphate-hormone, chemotherapeutic agent, or both?

AU - Walzer, Yair

AU - Oswalt, Joye

AU - Soloway, Mark S.

PY - 1984/1/1

Y1 - 1984/1/1

N2 - Estramustine phosphate, a combination steroid and alkylating agent, has been used for treatment of cancer of the prostate since 1969. We treated 32 patients with Stages C and D prostate cancer with this compound. Using the National Prostatic Cancer Project criteria of response, no patient achieved complete or partial objective response. Sixty-two per cent of the patients without prior hormonal manipulation and 12 per cent of those who were progressing following hormonal therapy met the criteria for a stable response. Both Stage C patients, 50 per cent of D1 and 28 per cent of D2 patients achieved disease stabilization for a mean duration of 14.8 months. There was no correlation between tumor grade and response to treatment. Fifty per cent of the patients whose elevated acid phosphatase declined remain stable, whereas 80 per cent in whom the acid phosphatase did not decline have progressed. Estramustine is effective in patients without prior hormonal manipulation. In those refractory to hormones, the prognosis is poor yet data exist to support the superiority of estramustine phosphate over conventional therapy.

AB - Estramustine phosphate, a combination steroid and alkylating agent, has been used for treatment of cancer of the prostate since 1969. We treated 32 patients with Stages C and D prostate cancer with this compound. Using the National Prostatic Cancer Project criteria of response, no patient achieved complete or partial objective response. Sixty-two per cent of the patients without prior hormonal manipulation and 12 per cent of those who were progressing following hormonal therapy met the criteria for a stable response. Both Stage C patients, 50 per cent of D1 and 28 per cent of D2 patients achieved disease stabilization for a mean duration of 14.8 months. There was no correlation between tumor grade and response to treatment. Fifty per cent of the patients whose elevated acid phosphatase declined remain stable, whereas 80 per cent in whom the acid phosphatase did not decline have progressed. Estramustine is effective in patients without prior hormonal manipulation. In those refractory to hormones, the prognosis is poor yet data exist to support the superiority of estramustine phosphate over conventional therapy.

UR - http://www.scopus.com/inward/record.url?scp=0021672146&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021672146&partnerID=8YFLogxK

U2 - 10.1016/0090-4295(84)90388-1

DO - 10.1016/0090-4295(84)90388-1

M3 - Article

C2 - 6539998

AN - SCOPUS:0021672146

VL - 24

SP - 53

EP - 58

JO - Urology

JF - Urology

SN - 0090-4295

IS - 1

ER -